Long-Acting Intelligence

The living market intelligence system for Long-Acting Injectables.

Vectora structures the whole LAI ecosystem into one source: every company, drug, candidate and technology, ready to explore, monitor and build on.

Request access Coverage & method

The landscape today

Long-acting injectables, scoped as a field of their own.

In generalist pharma databases, long-acting injectables sit inside broader categories, so each analysis starts by rebuilding the landscape by hand. Vectora maintains the LAI field as a scope of its own: de-duplicated, updated as the field moves, and ready to query.

The only structured, queryable map of the Long-Acting Injectables landscape.

Coverage & grain

One ecosystem, modeled two ways.

The LAI landscape is modeled at two levels: the asset, to map the pipeline, and the product, to compare what is on the market. Companies, technologies, targets and indications connect the two in one queryable ontology.

Assets: map the field

Molecules, marketed and in the pipeline.

Each asset is a molecule × delivery technology × developer. Size the landscape and segment it by phase, technology, target or modality.

Products by market: compare what’s live

Brands, by regulatory authority.

Each product is a brand × authority. Read the real regulatory profile: FDA against EMA, label by label.

The dimensions you can cross

Delivery technology

MicrosphereNanocrystalEngineered particleIn-situ depotGel depotImplantLiposomeOil depotProdrug / esterCleavable conjugateMatrix materialPEGylationLipidationAlbumin-bindingFc-fusionGlyco-engineeringProtein-fusion extender

Molecule

API classModalityTargetRouteLocal vs systemic effectMW / logP / PSA

Clinical

Therapeutic areaIndicationDevelopment phaseDuration of actionDosing interval

Regulatory: FDA & EMA

Approval by authorityBoxed warningCold chainStorageInjection sitesVolumesStrengthsExcipients

Every dimension shows how completely it is documented across the scope, so you always know how complete a given view is.

One platform, three products

Explore, monitor, produce.

One dataset feeds all three products, each unlocked for your organization as it becomes available.

Available

Atlas

Explore the entire LAI landscape across dozens of dimensions: size a segment, position an asset, spot the white space, compare brands and markets.

Available

Inbox

A five-minute read on the field, every two weeks: read-outs, approvals, deals, publications.

Planned

Studio

Briefs and reports generated on demand, each claim traceable to its source.

Atlas explores · Inbox monitors · Studio produces.

Direct data access. For teams that need the dataset in their own tools, a custom API or data export can be set up on request, scoped to your use case.

Atlas · Available

Explore the landscape from every angle.

Filter the landscape to the assets you care about, then read it through a lens: a sortable table, a competitive landscape, market trends over decades, a positioning map that exposes white space, and a side-by-side comparison across brands and markets.

Curated by an LAI specialist. Regulatory facts link to their official FDA and EMA labels.

Atlas table view scoped to the central nervous system: one row per asset with company, API class, technology and physical release — **Table.** Every asset in scope, one row each, here scoped to the central-nervous-system field.

Companies ranked by number of LAI assets, stacked by API class — **Who leads the field.** Companies ranked by LAI assets, split by API class.

Heatmap of technology families (DDS and HLE) by route of administration — **Route × technology families.** Every delivery and half-life-extension family against its route; empty cells are white space.

Heatmap of technology families by API class — **API class × technology families.** Which molecules each technology actually carries.

Assets plotted by molecular weight against polar surface area, colored by physical release family and sized by duration of action, scoped to the central nervous system — **Position map.** Assets by molecular weight against polar surface area, colored by delivery technology, sized by duration of action.

Assets by development stage, split by local or systemic effect — **Pipeline by stage.** From preclinical to marketed, split by local or systemic effect.

Cumulative market entries over time, by duration of action — **Market entries over time**, by duration of action.

Market composition by duration of action, 2010 versus 2025 — **Duration-of-action mix**, 2010 vs 2025.

Market growth by therapeutic area over time — **Market growth by therapeutic area**, 1952 to today.

Atlas Compare view: six brands side by side, FDA and EMA labels with divergences highlighted — **Compare.** Several brands side by side, FDA against EMA, divergences highlighted (here, the same brand is Otsuka on FDA and Lundbeck on EMA).

Inbox · Available

Track the field, period after period.

Each period, the main developments across long-acting injectables (readouts, approvals, deals, regulatory changes), filtered to the scope and structured the same way Atlas is. Read the current brief, search the full archive across periods, and export the slice you need as a clean PDF to circulate to your team.

Every item links to its official source: the press release, the label or the trial registry.

An Inbox issue: the period's material moves across the LAI field, each item linked to its source — A period’s brief: the material moves across the field, each traced to its source.

Inbox Explore: every item across periods, filtered by section, therapeutic area, molecule or technology, with PDF export — **Explore** — filter by section, therapeutic area, molecule or technology, then export the selection.

An Inbox PDF export: the selected items, each with its source link — **The export.** A clean PDF of your selection, every item linked to its source, ready to circulate.

For your team

Built for the questions each team asks.

The same dataset, read through the lens of each role.

Business Development

“Who competes directly in Phase 3 schizophrenia LAIs, and who develops them?”

Competitive Intelligence

“Are new LAIs trending toward longer intervals, and toward subcutaneous delivery?”

Medical Affairs

“Which LAIs reach a six-month dosing interval, and in which indications?”

Regulatory

“For this brand, what differs between the FDA and the EMA label?”

Marketing

“How many approved LAI products need cold-chain storage, and in what presentations?”

R&D / Strategy

“Where are the white spaces: which technology × therapeutic-area crossings have no asset yet?”

The analyst behind Vectora

Frank Issartel, PharmD

More than a decade in pharmaceutical competitive intelligence.

That domain work is built into the dataset: the scope, the ontology, the delivery-technology taxonomy.

You work directly with the analyst who builds and maintains the dataset.